Literature DB >> 7393249

Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol.

H R Ochs, G Carstens, D J Greenblatt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7393249     DOI： 10.1056/NEJM198008143030705

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  38 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

2.  In vitro binding of lidocaine to liver tissue under the influence of propranolol: another mechanism of interaction?

Authors:  C Tesseromatis; A Kotsiou; M Tsagataki; E Tigka; J Vovou; A Alevizou; C Perisanidis; T Saranteas; D Karakitsos; A Karabinis; G Kostopanagiotou
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Oct-Dec       Impact factor: 2.441

3.  Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin.

Authors:  H Y Pan; J Triscari; A R DeVault; S A Smith; D Wang-Iverson; B N Swanson; D A Willard
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 4.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 5.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 6.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

7.  Lidocaine increases lung uptake of propranolol.

Authors:  J A Pang; T R Williams; J P Blackburn; D W Holt; D M Geddes
Journal:  Lung       Date:  1986       Impact factor: 2.584

Review 8.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

9.  The impairment of lignocaine clearance by propranolol--major contribution from enzyme inhibition.

Authors:  N D Bax; G T Tucker; M S Lennard; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

10.  Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man.

Authors:  J O Miners; L M Wing; K J Lillywhite; R A Robson
Journal:  Br J Clin Pharmacol       Date:  1985-09       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.